|
- Scleroderma-Associated Interstitial Lung Disease (SSc-ILD)
Scleroderma-associated interstitial lung disease, or “SSc-ILD”, is a chronic lung disease in which scar tissue (“fibrosis”) and or inflammation builds up in the walls of the air sacs of the lungs in a person with a diagnosis of scleroderma (also called “systemic sclerosis” or “SSc”)
- Treatment and prognosis of interstitial lung disease in . . . - UpToDate
The treatment and prognosis of SSc-ILD will be reviewed here The clinical presentation and diagnosis of SSc lung disease, the treatment of SSc in general, and the treatment of SSc-associated pulmonary arterial hypertension are discussed separately
- Treatment of Systemic Sclerosis-associated Interstitial Lung Disease . . .
Background: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in patients with systemic sclerosis (SSc) To date, clinical practice guidelines regarding treatment for patients with SSc-ILD are primarily consensus based
- What Is SSC-ILD? Causes, Symptoms, and Treatments
SSc-ILD develops as a consequence of systemic sclerosis, an autoimmune disease where the immune system attacks healthy body tissues This immune response causes inflammation and excessive production of collagen, leading to the hardening and thickening characteristic of scleroderma
- Systemic sclerosis interstitial lung disease: unmet needs and . . . - Nature
Systemic sclerosis (SSc), or scleroderma, is a rare, systemic autoimmune disease that is associated with high mortality, often resulting from cardiopulmonary complications such as interstitial
- Systemic Sclerosis-AssociatedInterstitial Lung Disease (SSc-ILD)
Explore information on SSC Interstitial Lung Diseases (ILDs), including resources, clinical trials, congresses, support tools
- Systemic Sclerosis Associated Interstitial Lung Disease: New Directions . . .
A subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure
- American Journal of Respiratory and Critical Care Medicine
Background: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in patients with systemic sclerosis (SSc) To date, clinical practice guidelines regarding treatment for patients with SSc-ILD are primarily consensus based
|
|
|